J&J to pay more than $1.6B in HIV drugs promotion case

Sundry Photography/iStock Editorial via Getty Images Johnson & Johnson ( NYSE: JNJ ) unit Janssen was ordered to pay $1.64B after a New Jersey federal court jury found the drugmaker guilty of marketing two HIV drugs for off-label uses. Judge Zahid Quraishi in Trenton said that Janssen must pay $360M.